Business - Briefly   

Natco Pharma launches Bortenat

HYDERABAD: Natco Pharma Limited, a Hyderabad-based pharmaceutical company, has announced the launch of its brand of Bortenat (Bortezomib) 3.5 mg injection used in the treatment of multiple myeloma. Bortenat will be priced at Rs. 16,800 as against Rs. 75,000 of the imported medicine and since it was a pre-1995 invention, Natco was not expecting any patent litigation around the molecule.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

ASEAN agrees to resume free trade talks with India
Samsung plans second unit
VSNL to invest $600 m in submarine cables
Ascott inks pact with Rattha Group
Ducati forms JV with Kinetic group
BEA Systems to expand India operations
RIL perks up Sensex
Rupee ends further lower
Exchange rates
Bullion rates
Mittal group appoints consultant
SBI board ratifies PLR hike
RBI notification on relief bonds
Tata Steel to raise $750 m syndicated loan
SEZ approvals
PET jar manufacturing unit in Coimbatore
NI launches NI CompactDAQ
Airtel's instant GPRS for prepaid customers
Punj Lloyd JV with German company
City Union Bank launches CUB 400
ICICI Prudential launches two new products
Natco Pharma launches Bortenat
Everonn files draft prospectus with SEBI
Infotech appoints new President
Sonata offers 15 p.c. off on watches
Narrative fluency dictionary released
ISO 9001:2000 for Canara Traders and Printers
Orbit files draft prospectus with SEBI
New President and COO for Flextronics Software
ICICI Bank card utsav underway
Tegic launches XT9 mobile software
Deep Industries to tap market
Bharti signs contract with Ericsson

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu